Goldenwell Biotech, Inc.
GWLL
$0.70
-$0.07-9.09%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -200.27% | 200.00% | 0.00% | 62,200.00% | 7,360.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -200.27% | 200.00% | 0.00% | 62,200.00% | 7,360.00% |
| Cost of Revenue | 174,900.00% | -- | -- | -150.00% | -125.00% |
| Gross Profit | -212,100.00% | -- | -- | 8,400.00% | 0.00% |
| SG&A Expenses | -2.11% | -22.24% | -13.28% | 1.28% | -17.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 158.55% | 113.61% | 130.86% | 1.02% | -17.76% |
| Operating Income | -192.75% | -142.96% | -162.01% | 20.17% | 17.44% |
| Income Before Tax | -160.80% | -119.28% | -147.49% | 16.83% | 13.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.80% | -119.28% | -147.49% | 16.83% | 13.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.80% | -119.28% | -147.49% | 16.83% | 13.29% |
| EBIT | -192.75% | -142.96% | -162.01% | 20.17% | 17.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -150.00% | -107.14% | -138.46% | 8.33% | 14.29% |
| Normalized Basic EPS | -185.71% | -150.00% | -150.00% | 0.00% | 12.50% |
| EPS Diluted | -150.00% | -107.14% | -138.46% | 8.33% | 14.29% |
| Normalized Diluted EPS | -185.71% | -150.00% | -150.00% | 0.00% | 12.50% |
| Average Basic Shares Outstanding | 0.00% | 0.64% | 0.64% | 0.64% | 0.64% |
| Average Diluted Shares Outstanding | 0.00% | 0.64% | 0.64% | 0.64% | 0.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |